TRAILR2/TNFRSF10B Antibody (71908) [Phycoerythrin]

MDA-MB-231 human breast cancer cell line was stained with Mouse Anti-Human TRAIL R2/TNFRSF10B PE-conjugated Monoclonal Antibody (Catalog # FAB6311P, filled histogram) or isotype control antibody (Catalog # IC0041P, open histogram). View our protocol for Staining Membrane-associated Proteins.

Knockdown of K8 enhances TRAIL induced apoptosis(A-C) Cells were transfected with a control siRNA or siRNA specific to KRT8 transcript for 72 hours, followed by TRAIL stimulation (100 ng/ml [T47D and BT474] or 150 ng/ml [MCF7]) for 24 hours. The resultant cells were analyzed by immunoblotting using antibodies specific to K8/K18, DR4, DR5, caspase-3, caspase-8, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Caspase activation was identified by decrease in pro-enzyme form (ProC-8 and ProC-3). (D-F) Cells were treated as above and analyzed by flow cytometry after staining with Annexin-V-FITC and propidium iodide (PI). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

Keratin 8/18 overexpression downregulates total DR5 protein levels(A) MDA-MB-231 cells were transfected with a control plasmid or plasmid encoding human keratin 18 for 24 hours, followed by TRAIL stimulation (0, 5, 10 ng/ml) for 3 hours. The resultant cells were analyzed by immunoblotting using antibodies against K8/K18, DR5, DR4, caspase-8, caspase-3, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Caspase activation is indicated by a decrease in pro-enzyme form (ProC-8 and ProC-3) and by the simultaneous appearance of cleaved fragments. Results are from non-adjoining lanes from the same gel. (B) Relative total DR5 and DR4 protein levels were quantified using densitometry analysis of immunoblots in A and were normalized to GAPDH loading controls. P-values were determined using a student’s t-test. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

Knockdown of K8 enhances TRAIL induced apoptosis(A-C) Cells were transfected with a control siRNA or siRNA specific to KRT8 transcript for 72 hours, followed by TRAIL stimulation (100 ng/ml [T47D and BT474] or 150 ng/ml [MCF7]) for 24 hours. The resultant cells were analyzed by immunoblotting using antibodies specific to K8/K18, DR4, DR5, caspase-3, caspase-8, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Caspase activation was identified by decrease in pro-enzyme form (ProC-8 and ProC-3). (D-F) Cells were treated as above and analyzed by flow cytometry after staining with Annexin-V-FITC and propidium iodide (PI). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

K8/K18 physically interacts with DR5(A) Cell lysates from MCF7 and T47D cell lines were subjected to immunoprecipitation (IP) with an anti-K8/K18 antibody immobilized to protein A-agarose (lane 2 and 4) or with protein A-agarose alone (lane 1 and 3). IP samples were immunoblotted for DR5. (B) Cells were fixed, permeabilized, stained with anti-DR5 antibody (red) and anti-keratin 8 antibody (green), and analyzed by confocal microscopy. All images were acquired using a 40x objective lens. (C) MCF7 cells were transfected with control siRNA or siRNA against KRT8 for 72 hr. The resultant cells were fixed, permeabilized, and stained with anti-DR5 antibody (red), DAPI (nuclei, blue), and fluorescent phalloidin 488 for actin visualization (green). All images were acquired using a 40x objective lens. (D-F) Flow cytometry analysis of cells transfected with control siRNA or siRNA against KRT8. The resultant cells were harvested using a non-enzymatic cell dissociation solution. The cell samples were incubated with PE conjugated anti-DR5 antibody (IgG2b) or its corresponding IgG2b isotype as a control. (D) Shown are representative histograms of unstained cells (black dashed line), cells stained with the isotype control (red fill), and cells stained with PE-anti-DR5 antibody (blue outline with no fill). The right shift represents the presence of DR5 on the cell surface membrane. Median PE-anti-DR5 antibody fluorescence intensity for cells transfected with control siRNA and siRNA targeting keratin 8 are shown after subtraction of isotype control median fluorescence intensity in two independent experiments for T47D cells (E) and MCF7 cells (F). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

K8/K18 physically interacts with DR5(A) Cell lysates from MCF7 and T47D cell lines were subjected to immunoprecipitation (IP) with an anti-K8/K18 antibody immobilized to protein A-agarose (lane 2 and 4) or with protein A-agarose alone (lane 1 and 3). IP samples were immunoblotted for DR5. (B) Cells were fixed, permeabilized, stained with anti-DR5 antibody (red) and anti-keratin 8 antibody (green), and analyzed by confocal microscopy. All images were acquired using a 40x objective lens. (C) MCF7 cells were transfected with control siRNA or siRNA against KRT8 for 72 hr. The resultant cells were fixed, permeabilized, and stained with anti-DR5 antibody (red), DAPI (nuclei, blue), and fluorescent phalloidin 488 for actin visualization (green). All images were acquired using a 40x objective lens. (D-F) Flow cytometry analysis of cells transfected with control siRNA or siRNA against KRT8. The resultant cells were harvested using a non-enzymatic cell dissociation solution. The cell samples were incubated with PE conjugated anti-DR5 antibody (IgG2b) or its corresponding IgG2b isotype as a control. (D) Shown are representative histograms of unstained cells (black dashed line), cells stained with the isotype control (red fill), and cells stained with PE-anti-DR5 antibody (blue outline with no fill). The right shift represents the presence of DR5 on the cell surface membrane. Median PE-anti-DR5 antibody fluorescence intensity for cells transfected with control siRNA and siRNA targeting keratin 8 are shown after subtraction of isotype control median fluorescence intensity in two independent experiments for T47D cells (E) and MCF7 cells (F). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

Knockdown of K8 enhances TRAIL induced apoptosis(A-C) Cells were transfected with a control siRNA or siRNA specific to KRT8 transcript for 72 hours, followed by TRAIL stimulation (100 ng/ml [T47D and BT474] or 150 ng/ml [MCF7]) for 24 hours. The resultant cells were analyzed by immunoblotting using antibodies specific to K8/K18, DR4, DR5, caspase-3, caspase-8, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Caspase activation was identified by decrease in pro-enzyme form (ProC-8 and ProC-3). (D-F) Cells were treated as above and analyzed by flow cytometry after staining with Annexin-V-FITC and propidium iodide (PI). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29796187), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: Flow
• Clone: 71908
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Phycoerythrin

TRAILR2/TNFRSF10B Antibody (71908) [Phycoerythrin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
  Ile56-Glu182
  Accession # O14763
• Specificity: Detects human TRAIL R2 in direct ELISAs and Western blots. In direct ELISAs, does not cross-react with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or recombinant mouse TRAIL R2.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF10B
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 10 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  12 months from date of receipt, 2 to 8 degreesC as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR2/TNFRSF10B Antibody (71908) [Phycoerythrin]

• CD262 antigen
• CD262
• death domain containing receptor for TRAIL/Apo-2L
• Death receptor 5
• DR5
• DR5TRICK2B
• Fas-like protein
• KILLER/DR5
• KILLERapoptosis inducing protein TRICK2A/2B
• TNF-related apoptosis-inducing ligand receptor 2
• TNFRSF10B
• TRAIL R2
• TRAIL receptor 2
• TRAILR2
• TRAIL-R2apoptosis inducing receptor TRAIL-R2
• TRAILR2cytotoxic TRAIL receptor-2
• TRICK2
• TRICK2A
• TRICKB
• tumor necrosis factor receptor superfamily member 10B
• tumor necrosis factor receptor superfamily, member 10b
• tumor necrosis factor receptor-like protein ZTNFR9
• ZTNFR9

Background

Human TRAIL R2, also known as DR5 and TRICK 2, is a type 1, TNF R family, transmembrane protein which is a receptor for TRAIL (APO2 Ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR2/TNFRSF10B Antibody (FAB6311P)(42)

Publications using FAB6311P

• Romani, A;Lodi, G;Casciano, F;Gonelli, A;Secchiero, P;Zauli, G;Bortolini, O;Valacchi, G;Ragno, D;Bondi, A;Benedusi, M;Esposito, E;Voltan, R; Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells Cells 2024-10-11 [PMID: 39451196] (Flow Cytometry, Human)
• Christian Holmgren, Ellen Sunström Thörnberg, Victoria Granqvist, Christer Larsson Induction of Breast Cancer Cell Apoptosis by TRAIL and Smac Mimetics: Involvement of RIP1 and cFLIP Current Issues in Molecular Biology 2022-10-11 [PMID: 36286042]
• D Bernareggi, Q Xie, BC Prager, J Yun, LS Cruz, TV Pham, W Kim, X Lee, M Coffey, C Zalfa, P Azmoon, H Zhu, P Tamayo, JN Rich, DS Kaufman CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity Nature Communications, 2022-04-07;13(1):1899. 2022-04-07 [PMID: 35393416] (Flow Cytometry, Human)
• D Raman, P Tay, JL Hirpara, D Liu, S Pervaiz TRAIL sensitivity of nasopharyngeal cancer cells involves redox dependent upregulation of TMTC2 and its interaction with membrane caspase-3 Redox Biology, 2021-11-20;48(0):102193. 2021-11-20 [PMID: 34839142] (Flow Cytometry, Human)
• Tufano M, Cesaro E, Martinelli R et al. FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma Frontiers in Cell and Developmental Biology 2021-09-13 [PMID: 34589486]
• Yu Ren, Xue Wang, Shuaishuai Huang, Yangkai Xu, Guobin Weng, Rui Yu Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis Frontiers in Pharmacology 2021-03-25 [PMID: 33841136]
• S Martini, M Figini, A Croce, B Frigerio, M Pennati, AM Gianni, C De Marco, MG Daidone, C Argueta, Y Landesman, N Zaffaroni, A Satta Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody Cells, 2020-10-02;9(10):. 2020-10-02 [PMID: 33023194] (Flow Cytometry, Human)
• J Dittmann, T Haydn, P Metzger, GA Ward, M Boerries, M Vogler, S Fulda Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways Cell Death Differ., 2019-12-12;0(0):. 2019-12-12 [PMID: 31831875] (Flow Cytometry, Human)
• EB Jo, YS Lee, H Lee, JB Park, H Park, YL Choi, D Hong, SJ Kim Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells BMC Cancer, 2019-05-24;19(1):496. 2019-05-24 [PMID: 31126284] (Flow Cytometry, Human)
• Twomey JD, Zhang B. Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model Cancers (Basel) 1/15/2019 [PMID: 30650534]
• Twomey JD, Zhao L, Luo S et al. Tubulin couples death receptor 5 to regulate apoptosis. Oncotarget 12/4/2018 [PMID: 30613368]
• S Xu, D Li, T Li, L Qiao, K Li, L Guo, Y Liu miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin Cell. Physiol. Biochem., 2018-12-07;51(5):2212-2223. 2018-12-07 [PMID: 30537730] (Flow Cytometry, Western Blot, Human)
• B Lian, D Yang, Y Liu, G Shi, J Li, X Yan, K Jin, X Liu, J Zhao, W Shang, R Zhang miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis Cell. Physiol. Biochem., 2018-09-26;49(6):2151-2162. 2018-09-26 [PMID: 30257253] (Flow Cytometry, Human)
• C You, Y Yang, B Gao Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to ??-T Cell-Mediated Cytotoxicity Cell. Physiol. Biochem., 2018-08-23;49(1):235-244. 2018-08-23 [PMID: 30138935] (Flow Cytometry, Human)
• Bozza WP, Zhang Y, Zhang B. Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis Oncotarget 5/1/2018 [PMID: 29796187]
• Y Zhao, B Tian, Y Wang, H Ding Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5 Med. Sci. Monit., 2017-10-26;23(0):5096-5105. 2017-10-26 [PMID: 29070784] (Flow Cytometry, Human)
• D Jaworska, E Szliszka Targeting Apoptotic Activity Against Prostate Cancer Stem Cells Int J Mol Sci, 2017-07-29;18(8):. 2017-07-29 [PMID: 28758908] (Flow Cytometry, Human)
• HD Singh, I Otano, K Rombouts, KP Singh, D Peppa, US Gill, K Böttcher, PTF Kennedy, J Oben, M Pinzani, H Walczak, G Fusai, WMC Rosenberg, MK Maini TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis Sci Rep, 2017-07-17;7(1):5514. 2017-07-17 [PMID: 28717244] (Flow Cytometry, Human)
• Dimberg L, Towers CG, Behbakht K et al. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance Mol. Cancer Res 1/20/2017 [PMID: 28108622]
• Warat M, Sadowski T, Szliszka E, Krol W, Czuba Z The role of selected flavonols in tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) expression on activated RAW 264.7 macrophages. Molecules, 2015-01-08;20(1):900-12. 2015-01-08 [PMID: 25580686] (Flow Cytometry, Mouse)
• Chen Jun-Jie, Bozza William P, Di Xu et al. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget. 7/15/2014 [PMID: 25026275]
• Warat M, Szliszka E, Korzonek-Szlacheta I, Krol W, Czuba Z Chrysin, apigenin and acacetin inhibit tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) on activated RAW264.7 macrophages. Int J Mol Sci, 2014-06-27;15(7):11510-22. 2014-06-27 [PMID: 24979133] (Flow Cytometry, Mouse)
• Giorgio Zauli, Claudio Celeghini, Lorenzo Monasta, Monica Martinelli, Stefania Luppi, Arianna Gonelli et al. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival REPRODUCTION 2014-08-01 [PMID: 24825910]
• Calzolari A, Saulle E, De Angelis M, Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M, Testa U Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS ONE, 2014-04-16;9(4):e94438. 2014-04-16 [PMID: 24740347] (Flow Cytometry, Human)
• Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res, 2014-02-01;34(2):729-34. 2014-02-01 [PMID: 24511006] (Flow Cytometry, Rat)
• Kim , Seong Mu, Woo , Ji Sun, Jeong , Chang Hy, Ryu , Chung He, Jang , Jae-Deog, Jeun , Sin-Soo Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med, 2014-01-16;3(2):172-82. 2014-01-16 [PMID: 24436439] (Flow Cytometry, Human)
• Gupta , Subash C, Francis , Sajin K, Nair , Mangalam, Mo , Yin-Yuan, Aggarwal , Bharat B Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway. J Biol Chem, 2013-09-27;288(45):32343-56. 2013-09-27 [PMID: 24078627] (Flow Cytometry, Human)
• Di X, Zhang G, Zhang Y et al. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 9/1/2013 [PMID: 23988408]
• Gojo I, Tan M, Fang H, Sadowska M, Lapidus R, Baer M, Carrier F, Beumer J, Anyang B, Srivastava R, Espinoza-Delgado I, Ross D Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res, 2013-02-12;19(7):1838-51. 2013-02-12 [PMID: 23403629] (Flow Cytometry, Human)
• Hong S, Kim H, Kim J, Ha H, Kim Y, Bae E, Kim T, Lee K, Kim S Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J Biol Chem, 2012-12-19;288(5):3560-70. 2012-12-19 [PMID: 23255602] (Flow Cytometry, Human)
• Peppa , Dimitra, Gill , Upkar S, Reynolds , Gary, Easom , Nicholas, Pallett , Laura J, Schurich , Anna, Micco , Lorenzo, Nebbia , Gaia, Singh , Harsimra, Adams , David H, Kennedy , Patrick, Maini , Mala K Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med, 2012-12-17;210(1):99-114. 2012-12-17 [PMID: 23254287] (Flow Cytometry, Human)
• Jun-Jie Chen, H.-C. Jennifer Shen, Leslie A. Rivera Rosado, Yaqin Zhang, Xu Di, Baolin Zhang Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells Oncotarget 2012-08-19 [PMID: 22909995]
• Kalb ML, Glaser A, Stary G, Koszik F, Stingl G TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol., 2012-01-09;188(4):1583-91. 2012-01-09 [PMID: 22231699] (Flow Cytometry, Human)
• Sireesha V. Garimella, Andrea Rocca, Stanley Lipkowitz WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis Molecular Cancer Research 2012-01-01 [PMID: 22112940]
• H Rauert, T Stühmer, R Bargou, H Wajant, D Siegmund TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms Cell Death & Disease 2011-08-18 [PMID: 21850048]
• Szliszka E, Helewski KJ, Mizgala E, Krol W The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int. J. Oncol., 2011-07-06;39(4):771-9. 2011-07-06 [PMID: 21743964] (Flow Cytometry, Human)
• Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res, 2011-03-08;17(10):3181-92. 2011-03-08 [PMID: 21385927] (Flow Cytometry, Human)
• Bo Zhang, Hong Shan, Dan Li, Zheng-Ran Li, Kang-Shun Zhu, Zai-Bo Jiang et al. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5 Oncology Reports 2011-02-01 [PMID: 21152876]
• Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res., 2008-12-01;68(23):9614-23. 2008-12-01 [PMID: 19047138] (Flow Cytometry, Human)
• Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells, 2008-09-04;26(11):2955-63. 2008-09-04 [PMID: 18772312] (Flow Cytometry, Human)
• Wu CH, Kao CH, Safa AR TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum. Gene Ther., 2008-07-01;19(7):731-43. 2008-07-01 [PMID: 18476767] (Flow Cytometry, Human)
• Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med., 2007-03-12;204(3):667-80. 2007-03-12 [PMID: 17353365] (Flow Cytometry, Human)

Review for TRAILR2/TNFRSF10B Antibody (FAB6311P) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer Flow Human 01/27/2015

Summary

• Application: Flow Cytometry
• Sample Tested: See PMID: 22643355
• Species: Human

Bioinformatics

• Gene Symbol: TNFRSF10B
• Uniprot:
  • O14763()